Ignite Creation Date:
2024-05-06 @ 8:13 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06297603
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2024-03-01
Brief Title:
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin andor SGLT2 Inhibitor TRANSCEND-T2D-3
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase 3 Randomized Multicenter Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin andor SGLT2 Inhibitor
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin andor sodium-glucose cotransporter-2 SGLT2 inhibitor The study will last about 14 months and may include up to 22 visits
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J1I-MC-GZQA | OTHER | Eli Lilly and Company | None |